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trauma units routinely perform frequent venous duplex
screening examinations on high-risk patients. However, if
LMWH represents a more effective means of prophylaxis
for thromboembolism, routine venous duplex scanning
may be unnecessary for the care of these patients. Thus,
this study was undertaken to determine the utility of sur-
veillance venous duplex scanning to detect clinically
asymptomatic DVT in high-risk trauma patients who are
receiving enoxaparin and to determine whether the duplex
finding of asymptomatic DVT altered subsequent patient
management.
MATERIALS AND METHODS
The hospital medical records, including vascular labo-
ratory charts, of all patients admitted to the trauma service
at the University of Kentucky Level I trauma center for 30
consecutive months (January 1996 through June 1998)
were reviewed. All patients with multisystem trauma,
including neurosurgical trauma, were managed by the
trauma service. At the time of each patient’s admission,
the risk for development of DVT was assessed by the
admitting physician, who used a protocol of weighted fac-
tors (Table I). Each patient was risk stratified as low, mod-
erate, or high risk for thromboembolic events (Table II).
Appropriate use of low molecular weight heparin
(LMWH) is effective for reducing the incidence of deep
venous thrombosis (DVT) in a number of clinical situa-
tions. Such examples include patients with spinal cord
injury, those undergoing orthopedic procedures, and also
patients undergoing major surgical procedures for abdom-
inal or pelvic malignancy.1-3 LMWH has also been found
to be superior to unfractionated heparin as a prophylaxis
to prevent thromboembolism in high-risk patients with
trauma.4,5 Consequently, many trauma units have replaced
unfractionated heparin with LMWH in patients consid-
ered to be at “high risk” for development of DVT.
To detect DVT at its earliest presentation, many
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Enoxaparin treatment in high-risk trauma patients
limits the utility of surveillance venous duplex
scanning
Thomas H. Schwarcz, MD, Rhonda C. Quick, MD, David J. Minion, MD, Paul A. Kearney, MD,
Christopher J. Kwolek, MD, and Eric D. Endean, MD, Lexington, Ky
Objective: The value of surveillance venous duplex scanning for detecting unsuspected deep venous thrombosis (DVT)
in trauma patients who are receiving enoxaparin prophylaxis is open to question. This study was undertaken to deter-
mine whether enoxaparin reduced the clinical utility of surveillance scanning and whether management of these patients
was altered by findings of the scans.
Methods: The medical records of trauma patients who met defined criteria for high DVT risk, admitted during 30 con-
secutive months, were reviewed. These patients received enoxaparin 30 mg every 12 hours for the duration of their
admissions. Per protocol, surveillance lower extremity venous duplex scans were performed within 72 hours of enoxa-
parin administration and then weekly until patients were discharged from the hospital. The records were reviewed for
thromboembolic events (DVT or pulmonary embolism [PE]), patient location and ambulatory status, therapeutic
interventions (systemic anticoagulation, vena cava filter), and complications of enoxaparin therapy.
Results: A total 241 patients underwent 513 venous duplex examinations (1-13 per patient). Eight patients had DVT
on the initial scan; seven of these patients were asymptomatic. Five were treated with anticoagulation and/or vena cava
filter placement. Of the 233 patients with initially negative duplex scan results, five patients (2%) developed clinically
unsuspected lower extremity DVT while hospitalized. All of these five patients were in an intensive care unit. Three of
the five patients had no change in treatment. Two of the five underwent anticoagulation, and one vena cava filter was
placed. PE occurred in two hospitalized patients, one of whom was ambulatory, with negative duplex scan results. After
hospital discharge, six other patients had symptomatic DVT or PE despite in-hospital scans with negative results.
Complications associated with enoxaparin included hemorrhage (2) and thrombocytopenia (8).
Conclusions: After initial negative scan results, repeat surveillance duplex scanning during hospitalization detected a low
incidence (2%) of DVT in high-risk patients. Furthermore, the detection of unsuspected DVT altered the clinical man-
agement of less than 1% of the patients tested. Thus, after a venous duplex scan with negative results and initiation of
enoxaparin prophylaxis, subsequent surveillance duplex examinations are not warranted in asymptomatic trauma
patients. (J Vasc Surg 2001;34:447-52.)
The patients who were stratified to the high-risk group
were then given enoxaparin 30 mg subcutaneously every
12 hours. The dose was administered on admission, except
in patients with closed head injury, in patients with solid
organ injuries being managed nonoperatively, or in
patients with increased bleeding risks. For these patients,
the enoxaparin dosing was delayed for 48 hours, or occa-
sionally longer, and the patients had sequential compres-
sion devices placed on an uninjured extremity. When the
risk of bleeding complications was judged to be decreased,
these patients then started taking enoxaparin.
In addition, trauma patients were also given enoxa-
parin later in the hospital course if their risk factor score
increased. This change in treatment was made at the dis-
cretion of the attending physician, according to the factors
listed in Table I. Overall, 241 patients with trauma were
considered to be at high risk for development of DVT and
received enoxaparin for prophylaxis of thromboembolism
during their hospitalization.
As part of the trauma protocol, a lower-extremity
venous duplex examination was ordered within 72 hours
of initiation of enoxaparin therapy. The patients then had
weekly surveillance lower-extremity venous duplex scans
performed for the duration of their hospitalization or for
the duration of enoxaparin therapy. Duplex scans were
also performed if symptoms of pain or extremity edema
were noted. Upper-extremity examinations were not rou-
tinely performed for surveillance; therefore, the results of
studies performed on upper extremities of patients with
symptoms were not included in this study.
All venous duplex scans were performed in a labora-
tory certified by the Intersocietal Commission for the
Accreditation of Vascular Laboratories, or at the bedside,
with an Advanced Technologies Laboratories HDI
3000CV scanner (Advanced Technologies Laboratories,
Bothell, Wash) with a 7.4-MHz linear transducer. All
studies were interpreted by vascular surgeons who were
not directly involved with the daily management of the
patients. The lower-extremity venous system, from the
inguinal ligament to the ankle, bilaterally, was examined in
each patient, except when a splint or cast blocked access
for the probe. Each vein was assessed for compressibility,
phasicity, echogenicity, and augmentation. If a study was
interpreted as showing DVT at any location, the trauma
physician was immediately notified.
Each patient’s medical record was reviewed for occur-
rence of symptomatic or asymptomatic lower extremity
DVT, hospital location at the time of diagnosis (intensive
care unit [ICU], ward, or outpatient), and ambulatory sta-
tus at the time of the examination. The timing of initial
enoxaparin administration was examined in relationship to
time of admission. Interruption of enoxaparin therapy and
the duration of interruption were also noted. Treatment
was halted by the treating physician for thrombocytopenia
or clinical judgment of risk of hemorrhage. The records of
all patients with positive duplex study findings or throm-
boembolic events were specifically examined for treatment
changes, including initiation of systemic anticoagulation
or placement of vena cava filters. The occurrence of pul-
monary embolism (PE) and complications attributed to
enoxaparin therapy (eg, hemorrhage, thrombocytopenia,
heparin-induced thrombosis and thrombocytopenia) were
noted. Serial platelet counts were obtained in all patients.
The diagnosis of heparin-induced thrombosis and throm-
bocytopenia was made by a positive enzyme-linked
immunoassay for antibodies that bind to the platelet fac-
tor 4–heparin complex. Subsequent outpatient clinic
records were also reviewed for symptomatic thromboem-
bolic events occurring after hospital discharge.
The data were entered into a Microsoft Access database
and a Microsoft Excel spreadsheet (Microsoft Corporation,
Redmond, Wash) for quantitative analysis. Approval of this
clinical research study was obtained from the University of
Kentucky Medical Institutional Review Board.
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Table I. Risk for development of DVT, weighting of
factors
Risk factor Weight 
Immobility >5 d* 3
Repair or ligation of major venous injury* 3
History of thromboembolic disease* 3
Hypercoagulable state* 3
Complex lower-extremity fractures* 3
Pelvic fractures* 3
Spinal cord injury with deficit* 3
Age >75 y 3
>4 units transfusion in first 24 h 2
Surgical procedure >2 h 2
Immobility >72 h 2
Coagulopathy on admission 2
Intracranial hemorrhage 2
Spine fractures 2
Glasgow Coma Score <8 for >4 h 2
Cardiac disease 2
Varicose veins 2
Hormonal therapy 2
Postpartum <4 wk 2
Obesity 2
Malignancy 2
Age 60-74 y 2
Age 40-59 y 1
Central line >24 h 1
Inflammatory bowel disease 1
*Absolute high-risk criteria.
Table II. Definition of high-risk patients for DVT devel-
opment and treatment protocol
Risk factor score Risk category Prophylaxis
1 Low None
2-4 Moderate Heparin*/SCDS
≥5 High Enoxaparin
*Unfractionated heparin 5000 IU subcutaneously twice a day.
DVT, Deep venous thrombosis; SCDS, sequential compression devices.
RESULTS
Over a 30-consecutive month period, 241 patients
met the criteria for inclusion into this study. A total of 153
male and 88 female patients were treated. The mean age
of the patients was 42 years (range, 15-87 years).
Management of the traumatic injuries required 75 abdom-
inal, 22 pelvic, and 139 extremity operations. A total of
217 patients were managed in an ICU for at least 1 day
(range, 1-87 days; mean, 13 days). Only one patient was
known to have previously experienced an episode of DVT.
In 149 patients, enoxaparin was given after initial eval-
uation and coincided with the time of admission to the
trauma service. LMWH treatment was delayed in the
remaining patients because of concerns about potential
hemorrhage. In 60 patients, LMWH was initiated between
12 and 48 hours of admission. In 32 patients, enoxaparin
treatment was initiated more than 48 hours after admis-
sion. In 16 patients, the LMWH therapy was interrupted
for clinical reasons for at least one dose, and the average
duration of cessation was 104 hours (SD ± 76 hours).
Enoxaparin was discontinued completely in one patient.
A total of 513 lower extremity venous duplex examina-
tions were performed on the 241 patients (1-13 per
patient). The initial scan was performed in an ICU in 151
patients. Eight patients had DVT on the initial scan. All 8
patients had received enoxaparin within 72 hours of admis-
sion, and 6 of the 8 patients received their first enoxaparin
dose within 24 hours of admission. The initial scans in the
patients with positive scan results were performed between
1 and 10 days after admission (mean, 5 days).
Of the eight patients with initially positive venous
duplex scan results, seven were asymptomatic. Five of
these patients were managed with systemic anticoagula-
tion, and a vena cava filter was also placed in one. The
remaining three individuals continued to receive enoxa-
parin at prophylactic doses. Two of these three episodes of
DVT were thought to be directly related to femoral
venous line placement in the affected extremity. The third
patient had a DVT limited to a peroneal vein. 
Of the 233 patients with initially negative duplex scan
results, five (2%) developed clinically unsuspected DVT
during their hospitalization (Table III). All of these
patients were in an ICU and thus, nonambulatory. In
three of five patients, the first enoxaparin dose was admin-
istered on admission, one patient received enoxaparin 72
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hours after admission, and the initial dose in the fifth
patient was delayed until the eighth hospital day because
of a change in the patient’s risk score. However, this
patient received earlier DVT prophylaxis with unfraction-
ated heparin that was started on admission. In none of the
five patients was LMWH prophylaxis interrupted during
hospitalization.
Of these five patients who had clinically unsuspected
DVT, two were treated with systemic anticoagulation, and
one also had vena caval interruption. The other three
patients had no change in treatment, and a prophylactic dose
of enoxaparin was continued. The anatomic locations of the
DVT in asymptomatic patients are listed in Table III.
Interestingly, no unsuspected DVT was detected in any
patient until at least 12 days of hospitalization had occurred.
Two patients experienced PE during their initial hos-
pitalization for trauma. One patient was still in the ICU,
and PE was diagnosed by a high probability result on ven-
tilation-perfusion scan. The other patient was ambulatory
on the inpatient ward, and the embolus was diagnosed
within 72 hours of hospital admission with pulmonary
angiogram. Venous duplex scanning did not demonstrate
DVT in either of these patients.
Six patients returned as outpatients with thromboem-
bolic events (Table IV). One patient, discharged while
receiving enoxaparin, returned within 24 hours with a
symptomatic PE and asymptomatic DVT. This patient was
nonambulatory and had undergone a venous duplex
examination (with negative results) 72 hours before dis-
charge. A second patient returned 72 hours after discharge
with bilateral, symptomatic lower-extremity DVT, despite
low-dose warfarin treatment. At the time of diagnosis, his
international normalized ratio was 1.5, and the results of
his venous duplex examination 8 days earlier were nega-
tive. One patient discharged while on enoxaparin treat-
ment returned within 8 days with a symptomatic
lower-extremity DVT. He had a negative duplex study on
the day of hospital discharge. Two other patients returned
within 2 weeks; one returned with a symptomatic DVT
and the other died suddenly from saddle pulmonary
embolus and popliteal DVT. Both of these patients had
been discharged without posthospitalization DVT pro-
phylaxis because they were ambulating. One patient, who
did not receive prophylactic treatment after hospital dis-
Table III. Anatomic location of DVT, time of detection after admission, and treatment of patients with asymptomatic
DVT detected with surveillance venous duplex scans
Location (vein) First LMWH dose DVT detection Treatment
Common femoral Admission 12 d IV heparin
Common femoral Admission 14 d IV heparin/IVC filter
Peroneal 72 h 14 d None
Peroneal 8 d 32 d None
Posterior tibial Admission 21 d None
DVT, Deep venous thrombosis; IV, intravenous; IVC, inferior vena cava; LMWH, low molecular weight heparin. 
charge, returned with symptomatic lower-extremity DVT
and proven PE more than a month after release and was
treated with a vena cava filter.
There was one documented case of heparin-induced
thrombocytopenia in the 234 patients receiving enoxa-
parin. Eight other episodes of thrombocytopenia were
antibody negative, and enoxaparin was resumed without
event. There were two episodes of bleeding attributed to
enoxaparin therapy.
DISCUSSION
In the general population, results of venous duplex
scans are more likely to be normal when performed for
surveillance or for evaluation for a source of pulmonary
embolus (87% and 79% normal, respectively).6 If clinical
signs or symptoms are present (leg edema, calf tender-
ness), the duplex study findings are more likely to be pos-
itive.7 However, clinical signs and symptoms are not
specific for DVT. Since Bauer’s8 description of tibial frac-
tures and associated DVT, patients with trauma have long
been recognized to be at increased risk for thrombotic
events. In trauma patients who receive no form of pro-
phylaxis, DVT occurs in almost 60% of patients.9 Use of
unfractionated heparin or sequential compression devices
reduces the incidence of DVT to between 6% and 21%.9-
15 Geerts et al4 showed a 30% risk reduction in DVT for
the same high-risk population by replacing unfractionated
heparin with enoxaparin.
The use of surveillance venous duplex examinations
in patients with trauma has been widely reported, with
variable recommendations.16-20 Napolitano et al16 eval-
uated a twice weekly venous duplex surveillance proto-
col in 458 high-risk trauma patients. They observed a
10% incidence of asymptomatic DVT despite prophy-
laxis with unfractionated heparin or extremity compres-
sion devices. Most DVT episodes (67%) were diagnosed
on the initial venous duplex study, and 27% of DVT
episodes were detected by the second examination. On
the basis of multivariate analysis of risk factors, they rec-
ommended an aggressive venous duplex screening pro-
tocol for patients with the following characteristics: age
older than 60 years, Injury Severity Score more than 30,
Trauma and Injury Severity Score less than 85, or spinal
cord injury. They reported an incidence of PE of 0.2%,
presumably because of early detection of DVT with
immediate systemic anticoagulation or inferior vena cava
filter placement.
Piotrowski et al17 also examined the utility of surveil-
lance duplex scanning in high-risk trauma patients. They
used a surveillance protocol consisting of a baseline scan
within the initial 48 hours of admission, weekly scans for
3 weeks, followed by biweekly scans for another 3 weeks,
and then monthly scans until discharge. This approach
yielded a 5.8% incidence of DVT despite prophylaxis with
sequential compression devices or unfractionated heparin.
Of the episodes of DVT detected, 85% were asympto-
matic. Even with this aggressive surveillance protocol and
early treatment (systemic anticoagulation or caval inter-
ruption), PE still occurred in 1% to 2% of the patient pop-
ulation.
Gearhart et al18 evaluated a risk assessment profile
score using a surveillance protocol of weekly examinations
with additional examinations performed on the develop-
ment of symptoms. In the high-risk group, as determined
by the profile, the incidence of DVT was 10.8%, with 64%
of these being asymptomatic. The high-risk population
received prophylaxis of mechanical compression devices
and unfractionated heparin (81%) or enoxaparin (17%).
They recommended surveillance duplex scans be per-
formed only on high-risk patients on the basis of the risk
assessment profile score.
Meyer et al19 evaluated the utility and cost-effective-
ness of surveillance venous duplex scans in patients with
trauma. They found an incidence of asymptomatic DVT of
5% in a retrospective review and found that duplex study
findings were more likely to be positive if clinical symp-
toms were present (16% vs 5%). All of the patients were in
ICUs and were receiving unfractionated heparin or had
sequential compression devices. They noted that calf vein
DVT was more likely to be asymptomatic than proximal
vein DVT. The cost to identify each proximal DVT in
trauma patients in their ICU was $6688, and they esti-
mated that to survey all of the patients with trauma in
ICUs in the United States would cost $300 million per
year. This report recommended that routine duplex sur-
veillance was cost-effective only in patients with spinal
cord injury.
In the current study, a relatively aggressive protocol of
DVT prophylaxis with LMWH, specifically enoxaparin,
was instituted to reduce thromboembolic complications on
JOURNAL OF VASCULAR SURGERY
450 Schwarcz et al September 2001
Table IV. Clinical presentation of patients with thromboembolic events occurring after hospital discharge
Time of last 
Posthospital negative duplex study
Event Time since discharge DVT prophylaxis finding before discharge
DVT + PE 24 h Enoxaparin 72 h
DVT (bilateral) 72 h Warfarin 8 d
DVT 8 d Enoxaparin Day of hospital discharge
DVT + PE 2 wk None 48 h
DVT 2 wk None 72 h
DVT + PE 1 mo None 48 h
the trauma service. An analysis of the effectiveness of this
protocol in 595 patients showed a statistically significant
decrease in the incidence of DVT (6.4% to 3.6% in high-
risk patients), compared with a previous year in which
unfractionated heparin was used for prophylaxis 
in 630 patients (University of Kentucky Trauma Registry,
unpublished data, 1998). In general, adherence to the pro-
tocol was reasonably good. The University of Kentucky has
a detailed trauma registry, and there is essentially complete
information about death within 30 days of hospital dis-
charge. Thus, it is unlikely that any other patients died of
PE without our knowledge. Consequently, it appears that
the incidence of DVT and PE during hospitalization was
lower than that reported in previous studies, particularly
with regard to high-risk patients. The overall rate of asymp-
tomatic DVT, including the initial evaluation, was only 5%
(12/241) in this study.
If patients with initially positive venous duplex scan
findings are excluded from further analysis, the patients
with negative duplex scan findings subsequently experi-
enced a negligible incidence of DVT (2%). All episodes
occurred in patients in the ICU. Overall, 101 patients
were in the ICU for 10 or more days, and DVT developed
in only five patients. Three of the five experienced only
infrapopliteal vein thrombosis, which was not treated with
systemic anticoagulation. These five patients were fol-
lowed up with weekly duplex examinations, which showed
no propagation of thrombus. Thus, even with the unex-
pected finding of DVT, clinical management was altered in
only two of 233 patients (< 1%).
We think that this study is the first to specifically eval-
uate the utility of surveillance venous duplex scanning in
high-risk trauma patients who were universally treated
with LMWH to prevent DVT. It appears that enoxaparin
was effective in preventing proximal vein DVT in these
patients. These results are notable because this trauma
population had sustained significant injuries and many
patients remained in ICUs for weeks. Because LMWH
prophylaxis was more effective than expected, the role of
surveillance duplex scanning requires reassessment.
With an aggressive regimen of LMWH prophylaxis,
the incidence of DVT development in trauma patients dur-
ing hospitalization should be low. If the result of an initial
venous duplex scan is negative, there appears to be little, if
any, rationale for surveillance scans in asymptomatic
patients. The only patients in whom surveillance scans may
have any clinical utility are those remaining in ICUs for
more than 2 weeks. With this information, we think that
the use of surveillance duplex scanning can be significantly
reduced in the management of patients with trauma. Such
a change in practice should reduce costs without compro-
mise in the quality of medical care. In our institution, high-
risk trauma patients now receive routine prophylaxis with
LMWH and no longer undergo surveillance venous duplex
scans. Duplex scans are reserved for patients demonstrating
clinical signs or symptoms of DVT and for patients who
have not been able to have LMWH for more than 72
hours. Finally, surveillance scans should not be obtained in
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any situation unless treatment with either systemic antico-
agulation or placement of a vena cava filter would be
implemented with a positive scan finding. 
Despite an aggressive protocol of inpatient LMWH
prophylaxis and venous duplex scanning, a substantial
component of the total thromboembolic morbidity and
mortality in this population occurred after hospital dis-
charge. Both DVT and PE were experienced by outpa-
tients. This information would suggest that prophylaxis
for DVT and PE may need to continue after hospital dis-
charge in certain high-risk patients (eg, those with pelvic
fractures or spinal cord injury and those requiring pro-
longed bedrest or rehabilitation), and perhaps until
patients achieve a normal ambulatory status.
We would like to extend our sincere appreciation to
the University of Kentucky Vascular Laboratory person-
nel, who performed the high-quality venous duplex scans
in these patients with notable diligence.
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DISCUSSION
Dr Michael Sobel (Syracuse, NY). The intuitive thought was
if you have a very good effective prophylactic method you prob-
ably do not need to survey those patients, because the incidence
of DVT will be very low. Then came along low molecular weight
heparin with better bioavailability and improved pharmacokinet-
ics. Maybe not any less bleeding but certainly more effective in
certain high-risk patients like total hip arthroplasty. 
But trauma patients are a very different group. They are very
heterogeneous. They are very challenging in terms of bleeding
complications, and the true incidence of DVT and pulmonary
embolism in trauma patients is still not crystal clear. It can range
in studies from 15% to 60%, and the incidence of a proximal DVT
may be different than the incidence of total DVT. 
A few caveats before I get to my questions. Of course this was
a retrospective study, not a prospective one, so we really do not
know how frequently the protocols were implemented accurately
or how often the serial surveillance scans were done according to
protocol, but given those caveats, how well did your patients fare?
Well, they fared very well, in fact, surprisingly well. Your incidence
of total DVT was about 6% to 7%, if you count some of the late-
comers, whereas other randomized trials have found incidences of
15% to 30% for total DVT. If you look at just proximal DVT,
those you would be treating actively, your incidence was 5%,
whereas many of the randomized trials suggest that proximal
DVT incidence is at least 8% or 9%. So your patients did very well.
They had fewer bleeding complications, too, less than 1%,
whereas the typical bleeding rate is about 3%.
This brings me to my question. Can you tell us more about
your high-risk patients? Some high-risk patients are higher risk
than others. What were their injury severity scores? How often
did they have long bone fractures or pelvic fractures, which are
especially high-risk problems? Essentially in that question is the
question, why do you think you got such good results with
enoxaparin, much better than other people did?
Dr Rhonda Quick. . . . The protocol was relatively well imple-
mented. Some delay in obtaining initial duplex scans is attribut-
able to patients being admitted on weekends, when the vascular
laboratory was not available for testing. The subsequent weekly
scans were very consistently performed because they were done
on the same day, so everyone who was on enoxaparin had weekly
surveillance venous duplex scans on a Wednesday.
Regarding your question about Injury Severity Score, we did
not include injury severity scores in the database. Other papers do
address injury severity scores as an indicator of risk for throm-
boembolic events. Our patient population is a combination of both
penetrating and blunt trauma, with a predominance of blunt
injuries. The majority of the people whom we considered high risk
had combined pelvic and lower extremity trauma. The one patient
group that is profoundly high risk, which is underrepresented in
this study, is the group of spinal cord injury patients (because they
were admitted to the neurosurgical services and they have their
own different protocols). This study reviewed the protocol used by
the trauma service, and it did exclude the high-risk patient popula-
tion of spinal cord injury.
Dr G. Patrick Clagett (Dallas, Tex). I may have missed it
but we have a lot of patients in whom we cannot use prophylaxis
with low molecular weight heparin because of potential bleed-
ing complications, and we do not do routine surveillance. My
question to you is, in your high-risk patients in whom you did
not use low molecular weight heparin, what is the incidence of
DVT, and do you really think routine surveillance is indicated in
those patients? 
Dr Quick. Our high-risk patients who had an increased risk of
bleeding still received enoxaparin. However, their treatment was
delayed about 72 hours after admissions, so if they had a nonop-
erative spleen or liver and remained stable, they were started on
enoxaparin therapy. When we analyzed the actual positives, there
was no difference in the timing of initial enoxaparin dose com-
pared with the people who did not develop DVT. I do not think
that they should be treated differently in regard to indication for
surveillance venous duplex.
